COLYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 60g, sodium chloride 1.46g, potassium chloride 0.745g, sodium bicarbonate 1.68g, sodium sulfate 5.68g, flavor 0.851g/pack (orange, lemon lime, cherry); per liter of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for COLYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy or barium enema exam.
After fasting for >3hrs, 240mL orally every 10mins or 20–30mL/min by NG tube until fecal discharge is clear. Usual dose 3–4L. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Correct fluid and electrolyte abnormalities prior to initiation. Increased risk of arrhythmias (eg, history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF or cardiomyopathy); do pre-dose and post-colonoscopy ECGs. History of seizures. Rule out GI obstruction or perforation. Maintain adequate hydration. Renal impairment. Pregnancy (Cat.C). Nursing mothers.
Isosmotic bowel cleanser.
Concomitant drugs that may increase the risk of fluid and electrolyte disturbances or adverse events. Drugs administered within 1hr of start of Colyte may not be absorbed. Increased risk of ischemic colitis with concomitant stimulant laxatives.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation; serious: colonic mucosal ulceration, ischemic colitis; rare: arrhythmias.
Colyte w. Flavor Packs—4L (disposable jug w. 3 flavor packs)
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments